MicroRNA-155 attenuates late sepsis-induced cardiac dysfunction through JNK and β-arrestin 2

Yu Zhou1,2, Yan Song3,1, Zahir Shaikh1

  • 1Department of Internal Medicine, College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA.

Oncotarget
|May 20, 2017
PubMed

Insights

MicroRNA-155 (miR-155) protects against cardiac dysfunction in late sepsis. This study shows miR-155 improves survival by reducing inflammation and restoring immune function in septic mice.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Molecular Medicine

Background:

  • Sepsis-induced cardiac dysfunction is a major cause of mortality.
  • Late sepsis is characterized by immunosuppression, but cardiac changes remain unclear.
  • MicroRNA-155 (miR-155) influences immune responses and cardiac function.

Purpose of the Study:

  • To investigate the role of miR-155 in cardiac dysfunction during late sepsis.
  • To explore the therapeutic potential of miR-155 in sepsis.

Main Methods:

  • Cecal ligation and puncture (CLP) model in C57BL/6 mice to induce early and late sepsis.
  • Systemic administration of miR-155 mimic.
  • Assessment of cardiac function, inflammatory markers, immune cell infiltration, and survival rates.

Main Results:

  • Increased miR-155 expression protected against sepsis-induced cardiac dysfunction, improving cardiac output and left ventricular function.
  • miR-155 reduced myocardial infiltration of macrophages and neutrophils, and attenuated inflammation via JNK signaling.
  • miR-155 mimic transfection decreased beta-arrestin 2 (Arrb2) expression, restoring immunocompetence and improving survival.

Conclusions:

  • Increased miR-155 expression attenuates cardiac dysfunction and improves survival in late sepsis.
  • miR-155 exerts its protective effects by targeting JNK-associated inflammation and Arrb2-mediated immunosuppression.

Related Concept Videos